Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 185
- 试验地点
- 1
- 主要终点
- Longitudinal evaluation of BMD of the central skeleton (lumbar spine).
研究概览
简要总结
Background:
Premature ovarian insufficiency (POI) is a condition in which women under the age of 40 years have absent or irregular menstrual cycles. POI can cause infertility, signs of menopause, osteoporosis, and other symptoms. Hormone replacement therapy (HRT) is a treatment that gives women extra hormones, such as estrogen and progesterone. HRT works well in adult women. Researchers want to find the most effective doses and regimens for adolescents.
Objective:
To monitor the effects of HRT on adolescents with POI.
Eligibility:
Female adolescents aged 11 to 19 years diagnosed with POI. Healthy volunteers are also needed.
Design:
All participants will have clinic visits every 6 months for 2 years. Each visit may last 2 days. Each visit may include:
Blood and urine tests.
A test of their heart function.
A test to measure the stiffness of their blood vessels. Participants will lie flat with a blood pressure cuff on a leg and a meter on the neck while the cuff inflates.
A test of their grip strength. Participants will squeeze a handheld device as hard as they can.
Two scans to measure bone density. For one, participants will lie on a table while a scanner passes along their body. For the other, participants will sit in a chair and insert their forearm, then their lower leg, into a scanner.
A test to measure skin pigmentation. Participants' skin will be touched lightly with a device.
An optional visual exam of the vagina. Some vaginal fluid may also be collected with a cotton swab/cytobrush.
Participants with POI will receive HRT. They will be given estrogen patches and progesterone pills.
详细描述
Study Description:
This is a study of adolescents with premature ovarian insufficiency (POI) and their response to hormone replacement therapy (HRT).
Objectives:
Primary:
To identify the phenotype and associated genotype of adolescents with POI at the time of diagnosis, including assessment of overall bone health of participants pre- and post-HRT treatment with respect to bone mineral density (BMD) and other skeletal endpoints.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 11 Years 至 19 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •INCLUSION CRITERIA:
- •Inclusion Criteria for POI Participants
- •To be eligible to participate in this study, an individual must meet all the following criteria:
- •Individuals aged 11-19 years, inclusive, at the time of enrollment.
- •Diagnosis of premature ovarian insufficiency.
- •Documentation of one elevated serum FSH measurement greater than the testing laboratory's upper reference range (for age/Tanner stage).
- •Identify as female (i.e., sex assigned at birth)
- •Negative pregnancy test.
- •Inclusion Criteria for Healthy Volunteers:
- •Individuals aged 11-19 years.
- •Identify as female (i.e., sex assigned at birth)
- •Negative pregnancy test.
- •Absence of known chronic disease
排除标准
- •Male participants are excluded from both study groups (POI and Healthy Volunteers) as POI affects only the female reproductive system, while pregnant participants are not eligible to have DXA or HRpQCT imaging for safety reasons.
- •Exclusion Criteria for POI participants:
- •An individual who meets any of the following criteria will be excluded from participation in this study:
- •POI in the setting of Turner syndrome.
- •Patients who screened positive for celiac disease.
- •Receipt of any medications including HRT determined by the investigator to affect bone metabolism 3 months prior to enrollment.
- •Any medical condition determined by the investigator to affect bone health will be excluded.
- •Presence of a medical, psychiatric, or social condition which, in the opinion of the investigator, would place undue burden on the subject, NIH resources, or increase risk of participation.
- •Report of sexual activity but refusal to use a copper intrauterine device or double barrier forms of contraception during the study.
- •Exclusion Criteria for Healthy Volunteers:
- •For healthy volunteers, all exclusion criteria will apply as for POI participants except for number 1.
研究组 & 干预措施
POI Patients
POI patients will be receiving transdermal 17 beta-estradiol and oral micronized progesterone.
干预措施: Progesterone (Drug)
POI Patients
POI patients will be receiving transdermal 17 beta-estradiol and oral micronized progesterone.
干预措施: Estrogen Patch (Drug)
Healthy Participants
Healthy Control Participants
结局指标
主要结局
Longitudinal evaluation of BMD of the central skeleton (lumbar spine).
时间窗: 2 years
measures of bone health, dual-energy x-ray absorptiometry (DXA) measures of skeletal sites other than the spine (DXA - hip/total body) will be evaluated longitudinally in POI participants and their BMD compared to healthy control participants. Using DXA, vertebral fractures assessment (VFA) will be performed in POI participants and compared to healthy control participants. In addition, BMD will be evaluated with respect to skin pigmentation and muscle grip strength.
次要结局
- Evaluate bone density and strength of the radius and tibia in participants with POI and compare with healthy controls.(2 years)
- Compare metabolic and cardiovascular parameters between participants with POI and healthy controls.(2 years)
- Assess muscle strength and lean body mass in participants with POI compared to healthy controls.(2 years)
- Analyze heart repolarization, arterial stiffness, and coagulation parameters in participants with POI versus healthy controls.(2 years)
- Compare the genetic background of participants with POI to healthy controls using whole genome sequencing.(2 years)
- Assess quality of life using COPM and Interest Checklist questionnaires.(2 years)
- Evaluate psychological health using the Beck Depression Inventory and Spielberger State/Trait Anxiety Inventory.(2 years)
- Compare menopausal profile, including ovarian hormone levels and responses to the Menopause Rating Scale, between participants with POI and healthy controls.(2 years)
- Assess health effects of a typical clinical HRT regimen over two years.(2 years)